Results 121 to 130 of about 311,648 (345)

Production of Living Nanoparticles for Blood Cancer Therapy [PDF]

, 2018
Current cancer therapies leave much to be desired because they are very harmful to the patient and cause a significant decrease in quality of life. Chimeric Antigen Receptors (CAR) are a promising novel approach for treating specific types of leukemia ...
Mitchell, Peter, Pierotti, Michael, Piro, Matthew   +2 more
core   +1 more source

FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism [PDF]

, 2019
A major target of insulin signaling is the FoxO family of Forkhead transcription factors, which translocate from the nucleus to the cytoplasm following insulin-stimulated phosphorylation.
Albrechtsen, N., Araki, E., Batista, T., Cai, W., Cederquist, C., Damasio, M., Enerback, S., Gupta, M., Homan, E., Kahn, C., Mann, M., Ramirez, A., Sakaguchi, M., Singh, S., Steger, M., Wang, C.   +15 more
core   +2 more sources

Microfluidic Hydroporation Platform for Effective Allogeneic CAR‐T Cell Production and Subsequent Functional Cytotoxicity Analysis

Advanced Materials Technologies, EarlyView.
The hydroporator platform employs controlled hydrodynamic deformation for efficient mRNA and CRISPR/Cas9 delivery into primary human T cells, enabling allogeneic CAR‐T cell manufacturing. It preserves cell functionality and drives potent gene editing, CAR expression, and tumor cytotoxicity, while feature‐based analysis links these functional outcomes ...
Soohyun Jeon, Sein Kim, Hyun‐Young Kim, Duck Cho, Sungsu Park, Seohyun Kim, Aram J. Chung   +6 more
wiley   +1 more source

Antimicrobial Functionalization of Surfaces by a Chimeric Adhesive Protein

ACS Applied Bio Materials
The main aim of this work is to account for the prevention and control of microbial growth on surfaces of interest in medical technology. Surface modification is often achieved by physiotherapy or chemical treatments that can involve time-consuming steps, hazardous reagents, and harsh conditions.
Rossana Pitocchi, Anna Pennacchio, Flavia Zuber, Qun Ren, Eugenio Notomista, Silvia Campioni, Gustav Nyström, Paola Giardina, Alessandra Piscitelli   +8 more
openaire   +4 more sources

Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans [PDF]

, 2013
Rabies kills many people throughout the developing world every year. The murine monoclonal antibody (mAb) 62-71-3 was recently identified for its potential application in rabies postexposure prophylaxis (PEP).
Anthony R. Fooks, Ashley C. Banyard, Bardor M., Benmansour A., Bianca Bulmer‐Thomas, Constantine D. G., Craig Dolleweerd, David Selden, Dietzschold B., Dietzschold B., Dietzschold B., Edward Wright, Fooks A. R., Friedrich Altmann, Gomord V., Hampson K., Hultberg A., Julian K.‐C. Ma, Knobel D. L., Lafay F., Lafon M., Leonard Both, Luo T. R., Ma J. K., Manning S. E., Mansfield K. L., McCormick A. A., Muhamuda K., Müller T., Prehaud C., Satpathy D. M., Seif I., Shantavasinkul P., Sudarshan M. K., Tacket C. O., Tekoah Y., Van Ree R., Warrell M., Wertheim H. F. L., World Health Organization, World Health Organization, Wright E., Zeitlin L.   +42 more
core   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Proteolysis Prevents in Vivo Chimeric Fusion Protein Import into Yeast Mitochondria. [PDF]

, 1995
Jianzhong Zhou, Yinglin Bai, Henry Weiner   +2 more
openalex   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Membrane topology of the ArsB protein, the membrane subunit of an anion-translocating ATPase [PDF]

, 1992
The ars operon of the conjugative R-factor R773 encodes an oxyanion pump that catalyzes extrusion of arsenicals from cells of Escherichia coli. The oxyanion translocation ATPase is composed of two polypeptides, the catalytic ArsA protein and the ...
Rosen, Barry P., Tisa, Louis S., Wu, Jianhua   +2 more
core   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source